TNNI3 and heart failure: The monitoring of NLR, PLR, NT-proBNP, cTn I, and ST2/IL-33R in DTC/−T2DM patients receiving 131I therapy over a long period may help to identify those at risk of developing cardiac complications, including heart failure, myocardial complications, and chronic cardiomyopathies.